C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
C型凝集素受体通路在结核病/艾滋病毒双重感染发病机制中的作用
基本信息
- 批准号:10159205
- 负责人:
- 金额:$ 77.57万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2018
- 资助国家:美国
- 起止时间:2018-04-01 至 2023-04-30
- 项目状态:已结题
- 来源:
- 关键词:Animal ModelAnti-Inflammatory AgentsAutopsyBiologicalBiological AssayBloodC Type Lectin ReceptorsCause of DeathCellsCessation of lifeChemicalsClinicalComplementCryopreservationDataDefectDevelopmentDiseaseDisease OutcomeDisease modelEpidemicFunctional disorderGenesGenetic TranscriptionHIVHIV InfectionsHIV/TBHumanImmuneImmune System DiseasesImmune responseImmunologyImmunosuppressionImpairmentIn VitroIndividualInfectionInflammationInflammatoryInflammatory ResponseInnate Immune ResponseInterventionInvestigationLungLung InflammationMediatingModelingMolecularMolecular BiologyMusMycobacterium tuberculosisOutcomePathogenesisPathologyPathway interactionsPatternPeripheral Blood Mononuclear CellPharmaceutical ChemistryPharmacotherapyPhasePositioning AttributePublic HealthPublishingPulmonary InflammationPulmonary TuberculosisReceptor SignalingRelapseReporterResearchResolutionRoleSamplingSignal PathwaySignal TransductionStructure of parenchyma of lungSurfaceSystemT-LymphocyteTestingTherapeuticTissue BanksTissuesTranscriptTuberculosisantiretroviral therapybaseco-infectioncytokinedesigndrug standardgain of functionhuman subjecthuman tissuehumanized mouseimmune functionimmunoregulationin vivoinfection riskinsightlung injurymacrophagemonocytemouse modelneutrophilnovelrepositoryresponserestorationsample collectiontherapeutic targettranscriptomevirology
项目摘要
Tuberculosis (TB) and Human immunodeficiency virus (HIV) cooperate to drive a deadly co-epidemic that
results in approximately 12 million new infections and 4.5 million deaths annually. TB is the leading cause of
death in people living with HIV infection, and the risk for new Mycobacterium tuberculosis (Mtb) infections and
TB relapse continue despite restoration of T cells by anti-retroviral (ARV) therapy. A spectrum of immune
dysfunction in human subjects with dual disease is well described, including both immune suppression and
inappropriate inflammation. The mechanistic bases for many of these outcomes of co-infected individuals,
however, are poorly understood and represent an important gap for development of host directed interventions
to: 1) restore protective immune responses, 2) reduce pulmonary damage, and 3) complement standard drug
therapy. We exploited our access to relevant human tissues and biologicals, and utilized our humanized mouse
co-infection model, to identify novel candidate mechanisms for co-infection pathophysiology. As a result, we
have preliminary data supporting an HIV-mediated effect to compromise the function of an immune-regulatory
C-type lectin receptor in lung macrophages (Mɸ). The objective of this R01 application is to identify HIV-mediated
defects in human Mɸ due to native and experimental infection, and demonstrate the impact of these defects in
the setting of pulmonary TB. Our hypothesis is that that HIV modulates immunoregulatory CLRs in pulmonary
Mɸ and compromises an important innate signaling pathway for recognition and resolution of tissue damaging
inflammation in Mtb-infected lungs. We propose the following two aims to test this hypothesis: 1) Determine how
compromise of immunoregulatory CLR pathways by HIV promotes pulmonary inflammation following Mtb
infection, and 2) Identify mechanism(s) whereby HIV compromises CLR pathways as therapeutic targets to
reduce inflammatory outcomes in Mtb/HIV co-infected lungs. These aims will be accomplished by using bio-
banked biologicals and tissue from HIV+ donors, in vitro systems, gene deficient mice, and humanized mice.
We are well positioned to carry out these studies as our interdisciplinary TB/HIV co-infection team includes
immunology, pathology, molecular biology, animal model, and medicinal chemistry expertise. In phase I, we
propose to demonstrate that HIV infection interferes with the anti-inflammatory function of MGL and demonstrate
the consequences of MGL dysfunction in the Mtb-infected lung. In phase II, we will establish the mechanisms
for HIV-mediated disturbance of MGL and explore novel CLR pathway targets as potential therapeutic
approaches to reduce pulmonary damage in the setting of TB.
结核病(TB)和人类免疫缺陷病毒(HIV)共同推动了一种致命的共同流行病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Janice J Endsley其他文献
Janice J Endsley的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Janice J Endsley', 18)}}的其他基金
Novel Stem Cell Immunotherapy for MDR-Tuberculosis
耐多药结核病的新型干细胞免疫疗法
- 批准号:
10418739 - 财政年份:2021
- 资助金额:
$ 77.57万 - 项目类别:
Novel Stem Cell Immunotherapy for MDR-Tuberculosis
耐多药结核病的新型干细胞免疫疗法
- 批准号:
10640122 - 财政年份:2021
- 资助金额:
$ 77.57万 - 项目类别:
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
C型凝集素受体通路在结核病/艾滋病毒双重感染发病机制中的作用
- 批准号:
9538016 - 财政年份:2018
- 资助金额:
$ 77.57万 - 项目类别:
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
C型凝集素受体通路在结核病/艾滋病毒双重感染发病机制中的作用
- 批准号:
10390479 - 财政年份:2018
- 资助金额:
$ 77.57万 - 项目类别:
C-type Lectin Receptor Pathways in the Pathogenesis of TB/HIV Co-infection
C型凝集素受体通路在结核病/艾滋病毒双重感染发病机制中的作用
- 批准号:
10092516 - 财政年份:2018
- 资助金额:
$ 77.57万 - 项目类别:
HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infection
HIV引起的肺巨噬细胞缺陷加剧结核分枝杆菌合并感染
- 批准号:
9335956 - 财政年份:2016
- 资助金额:
$ 77.57万 - 项目类别:
HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infection
HIV引起的肺巨噬细胞缺陷加剧结核分枝杆菌合并感染
- 批准号:
9204582 - 财政年份:2016
- 资助金额:
$ 77.57万 - 项目类别:
HIV-induced Defects in Pulmonary Macrophages Exacerbate Mycobacterium Tuberculosis Co-infection
HIV引起的肺巨噬细胞缺陷加剧结核分枝杆菌合并感染
- 批准号:
9129330 - 财政年份:2015
- 资助金额:
$ 77.57万 - 项目类别:
Self-assembling Peptide Nanomaterials for Eliciting Mucosal CD8+ T cell Immunity
用于引发粘膜 CD8 T 细胞免疫的自组装肽纳米材料
- 批准号:
9036015 - 财政年份:2015
- 资助金额:
$ 77.57万 - 项目类别:
A Humanized Mouse Model to Study HIV/Mtb Co-infection
研究 HIV/Mtb 合并感染的人源化小鼠模型
- 批准号:
7930463 - 财政年份:2010
- 资助金额:
$ 77.57万 - 项目类别:
相似海外基金
Development of small molecule inhibitors as anti-inflammatory agents and antidotes for arsenicals
开发作为抗炎剂和砷解毒剂的小分子抑制剂
- 批准号:
10727507 - 财政年份:2023
- 资助金额:
$ 77.57万 - 项目类别:
Discovery of New Anti-Inflammatory Agents to Treat COPD
发现治疗慢性阻塞性肺病的新型抗炎药
- 批准号:
9194162 - 财政年份:2016
- 资助金额:
$ 77.57万 - 项目类别:
Synthesis of anti-inflammatory agents and their structure-activity relationships studies
抗炎药的合成及其构效关系研究
- 批准号:
496858-2016 - 财政年份:2016
- 资助金额:
$ 77.57万 - 项目类别:
University Undergraduate Student Research Awards
NAAA Inhibitors as Anti-inflammatory Agents, Phase II
NAAA 抑制剂作为抗炎剂,II 期
- 批准号:
9201955 - 财政年份:2015
- 资助金额:
$ 77.57万 - 项目类别:
Novel flavonoids as anti-inflammatory agents in alcoholism
新型黄酮类化合物作为酒精中毒的抗炎剂
- 批准号:
8251289 - 财政年份:2014
- 资助金额:
$ 77.57万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8302750 - 财政年份:2012
- 资助金额:
$ 77.57万 - 项目类别:
Design and in vivo delivery of novel anti-inflammatory agents
新型抗炎剂的设计和体内递送
- 批准号:
267940 - 财政年份:2012
- 资助金额:
$ 77.57万 - 项目类别:
Operating Grants
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8403458 - 财政年份:2012
- 资助金额:
$ 77.57万 - 项目类别:
Development of inlammasome inhibitors to be used as anti-inflammatory agents
开发用作抗炎剂的inlammasome抑制剂
- 批准号:
8549297 - 财政年份:2012
- 资助金额:
$ 77.57万 - 项目类别:
TLR-7 Agonists as Targeted Anti-inflammatory Agents in Arthritis
TLR-7 激动剂作为关节炎的靶向抗炎药
- 批准号:
8472443 - 财政年份:2012
- 资助金额:
$ 77.57万 - 项目类别:














{{item.name}}会员




